A Promising Treatment for High-Risk Non-Muscle Invasive… : Oncology Times
An abstract is unavailable.
Related Articles
Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
Watch Free Movies & TV Shows Online | wedotv
Stream a wide selection of movies and TV shows for free on wedotv. No subscription needed – just hit play and enjoy unlimited entertainment!
JZP458 in ALL/LBL: Complete follow-up results from AALL1931 trial
We summarize the results of the complete analysis from the AALL1931 trial assessing the efficacy and safety of JZP458 in children and adult patients with…
Validation of updated ELN 2022 risk stratification in adult patients with AML
Ruhnke et al. published a retrospective cohort study in Blood Advances validating the prognostic value of the 2022 ELN classification in patients with newly diagnosed…
De-escalating treatment in patients with breast cancer post-surgery
Icro Meattini, MD, University of Florence, Florence, Italy, comments on the current treatment strategies for patients after breast cancer surgery, highlighting the optimization of de-escalation…
Results of a Phase II trial investigating loncastuximab tesirine + rituximab in high-risk R/R FL
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, presents the results of a Phase II investigator-initiated study (NCT04998669) investigating a combination of loncastuximab tesirine…
Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Key PointsCD37 is a surface receptor present on most AML blasts, which has unique internalization properties when compared with normal blood cells.Treatmen
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
PURPOSEDenileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial…